<DOC>
	<DOCNO>NCT03003650</DOCNO>
	<brief_summary>First-In-Man Study ACURATE TF™ Transfemoral Aortic Bioprosthesis Implantation Patients Severe Aortic Stenosis collect human feasibility data pertain safety performance device .</brief_summary>
	<brief_title>ACURATE TF™ Transfemoral Aortic Bioprosthesis Implantation Patients With Severe Aortic Stenosis ( 2011-03 )</brief_title>
	<detailed_description>A single arm , prospective , multicenter , non-randomized , open trial , 5 Years follow-up Symetis ACURATE TF™ Transfemoral Aortic Bioprosthesis minimal invasive implantation via transfemoral access treat patient severe aortic stenosis conventional aortic valve replacement ( AVR ) via open heart surgery consider associate high risk evaluate feasibility performance implantation safety 30-Day Follow-up .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Patients 75 year age old 2 . Logistic EuroSCORE ≥ 20 3 . Severe aortic stenosis characterize mean aortic gradient &gt; 40 mmHg peak jet velocity &gt; 4.0 m/s aortic valve area &lt; 1.0 cm2 4 . NYHA Functional Class &gt; II 5 . Aortic annulus diameter ≥ 21mm ≤ 27mm TEE 6 . Patient surgical candidate due significant comorbid condition unrelated aortic stenosis 7 . Patient willing participate study provide sign informed consent 1 . Unicuspid bicuspid aortic valve 2 . Extreme eccentricity calcification 3 . Severe mitral regurgitation ( &gt; 2+ ) 4 . Preexisting prosthetic heart valve position / prosthetic ring 5 . Aortic peripheral anatomy NOT appropriate transfemoral implant 6 . Thoracic ( TAA ) abdominal ( AAA ) aortic aneurysm 7 . Presence endovascular stent graft treatment TAA AAA 8 . Transesophageal echocardiogram ( TEE ) contraindicate 9 . LVEF &lt; 30 % ECHO 10 . ECHO evidence intracardiac mass , thrombus , vegetation 11 . AMI within 1 month prior implant procedure 12 . PCI , except balloon valvuloplasty ( BAV ) within 1 month prior implant procedure 13 . Previous TIA stroke within 3 month prior implant procedure 14 . Active ulcer gastrointestinal ( GI ) bleed within 3 month prior implant procedure 15 . Any scheduled surgical percutaneous procedure perform prior 30 day visit 16 . History bleed diasthesis coagulopathy refusal blood transfusion 17 . Systolic pressure &lt; 80mmHg , cardiogenic shock , need inotropic support IABP 18 . Primary hypertrophic obstructive cardiomyopathy ( HOCM ) 19 . Active infection , endocarditis pyrexia 20 . Hepatic failure 21 . Chronic renal dysfunction serum creatinine &gt; 2.5 mg/dL renal dialysis 22 . Refusal surgery 23 . Severe COPD require home oxygen 24 . Neurological disease severely affect ambulation daily function , dementia 25 . Life expectancy &lt; 12 month due noncardiac comorbid condition 26 . Known hypersensitivity/contraindication study medication , contrast medium , nitinol 27 . Currently participate investigational drug another device study</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Severe Symptomatic Aortic Valve Stenosis</keyword>
</DOC>